Stock Ratings / Health Care / TRLV / forecast

CRON (52) RGC (38) DFTX (52) TLRY (32) ⌘ Pro Terminal →

Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) 12-Month Stock Forecast & Price Target Cone

$10.60 -0.19% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.58

Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $2.04B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.58 (-0.22%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 19.4% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY • 52.7% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE+0% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TRLV)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (58/100 Composite)

🔍 WHY TRLV SCORES 58/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+16/20 pts (28% of score)

FRED Regime × Technicals: 69% of 52W Range • RSI-14 at 43.3 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Cash Engine Quality+13/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 19.4% FCF Margin ($228.6M FCF) & 60.2% Gross Margin

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk8/20 pts (-12 pt drag)

Balance-sheet & 10-K footnote risk deducts 12 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$10.67-6.2% Next Q

Q2 (-2Q)

Grade C+$10.01+4.1% Next Q

Q3 (-1Q)

Grade C$10.42+1.7% Next Q

Current

Grade D+$10.60+0% Hist 90D α

Trajectory: B- (66) → D+ (58)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the TRLV Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 58/100 (D+) score, TRLV faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 57.7% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($11.19) or 200D SMA ($8.82) invalidates the momentum regime and cuts Target Base ($10.60) toward Bear Floor ($8.27).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TRLV• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “TRLV Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 58%NO 42%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your TRLV Position Size: $10,000

Shares at $10.60: 943.4 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $8.27

$7,802

$-2,198 (-22.0%)

12M Consensus BaseTarget $10.60

$10,000

+$0 (+0.0%)

12M Bull Case BreakoutTarget $13.94

$13,151

+$3,151 (+31.5%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$11	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$13	69%	B
JP MorganUS Large-Cap Research	HOLD	$9	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TRLV)

✓Walkthrough of TRLV's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

TRLV // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +7.72%▲ ASCENDING CHANNEL

2026-10-30O $10.46H $10.60L $9.90C $10.60VOL 1.41M

RES: $14.83SUP: $8.65SMA50: $11.19SMA200: $8.82

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TRLV Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TRLV Butterfly Map → + Track TRLV →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

3.1%/yr Implied 5Y Growth

vs. -0.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on TRLV today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TRLV. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for TRLV today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TRLV)

Health Care Rank #225 of 1016 ⚔️ CRON vs TRLV Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TRLV vs. CRON, RGC, DFTX, TLRY)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) ranks #225 by composite RQD confidence (58/100, grade D+) and #258 by equity capitalization ($2.04B). Within this direct 5-issuer industry benchmark cohort, TRLV leads on earnings valuation at N/A trailing P/E, while TRLV leads on capital efficiency and profitability with 12.8% ROIC and 60.2% gross margin. TRLV currently leads its immediate peer cohort in composite quantitative strength at 58/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
TRLV ACTIVE Trulieve Cannabis Corp. Subordinate Voting Shares	D+	58/100	—	60.2%	12.8%	-0.19%	$2.04B	Benchmark Subject
CRON Cronos Group Inc. Common Share	D+	52/100	—	42.8%	-4.5%	+0.30%	$1.24B	/cron-vs-trlv →
RGC Regencell Bioscience Holdings Limited	D-	38/100	—	—	—	-5.64%	$3.40B	/rgc-vs-trlv →
DFTX Definium Therapeutics Inc.	D+	52/100	—	—	-32.2%	-0.37%	$5.10B	/dftx-vs-trlv →
TLRY Tilray Brands Inc.	E	32/100	—	28.4%	-3.9%	-1.86%	$390.2M	/tlry-vs-trlv →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001754195

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) reported GAAP revenue of $1.18B (-0.4% vs. FY2024 revenue of $1.19B , and +4.6% cumulative change since FY2023) , GAAP net income of -$116.4M, operating cash flow of $272.8M, and free cash flow of $228.6M (+53.6% YoY). On the balance sheet, TRLV closed FY2025 with $2.70B in total assets against $0 in total debt (Altman Z-Score: 1.12, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.18B	-$116.4M	$272.8M	$228.6M	$2.70B	—
FY2024 (FY)	2024-12-31	$1.19B	-$155.1M	$271.5M	$148.9M	$2.87B	—
FY2023 (FY)	2023-12-31	$1.13B	-$526.8M	$201.8M	$201.8M	—	—

3. TRLV Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TRLV stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Trulieve Cannabis Corp. Subordinate Voting Shares (NYSE: TRLV) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $10.60 (-0.19% 1D, market cap $2.04B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, TRLV ranks #225 in composite RQD confidence.

How does TRLV compare to CRON and RGC in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), TRLV carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of 60.2%, and ROIC of 12.8%. By comparison, CRON (Cronos Group Inc. Common Share) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -4.5%, cap $1.24B) and RGC (Regencell Bioscience Holdings Limited) posts a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $3.40B). Among the 5-stock peer group, TRLV leads on earnings multiple (N/A) while TRLV leads on capital efficiency (12.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TRLV?

Per TRLV's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001754195), Trulieve Cannabis Corp. Subordinate Voting Shares generated $1.18B in revenue (-0.4% YoY), -$116.4M in net income, and $228.6M in free cash flow against $2.70B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TRLV trading relative to its 50-day, 200-day, and 52-week technical levels?

TRLV last traded at $10.60 (-0.19% on volume of 1,034,372 shares), positioning the stock -5.27% below its 50-day simple moving average ($11.19) and +20.18% above its 200-day simple moving average ($8.82). Across its 52-week range of $4.62 to $13.28, TRLV sits at the 69.1% percentile with a 14-day RSI of 43.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.28 to $11.92).

TRLV Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is TRLV's 12-month stock price target?

Trulieve Cannabis Corp. Subordinate Voting Shares (TRLV) carries a 12-month consensus base price target of $10.6 (+0% from $10.60), with a bull-case target of $13.94 and a bear-case floor of $8.27.

Is TRLV stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates TRLV D+ (Sell — SELL) with an RQD Confidence score of 58/100.

Direct Sub-Reports: TRLV RQD Cockpit TRLV 12M Forecast TRLV Earnings & Move TRLV Dividends & DRIP TRLV Insiders & 13F TRLV Whale Options TRLV Profit Sankey TRLV News & Why